Mechanistically driven therapies for atrial fibrillation (AF), the most common cardiac arrhythmia, are urgently needed, the development of which requires improved understanding of the cellular signaling pathways that facilitate the structural and electrophysiological remodeling that occurs in the atria. Similar to humans, increased persistent Na + current leads to the development of an atrial myopathy and spontaneous and long-lasting episodes of AF in mice. How increased persistent Na + current causes both structural and electrophysiological remodeling in the atria is unknown. We crossbred mice expressing human F1759A-Na V 1.5 channels with mice expressing human mitochondrial catalase (mCAT). Increased expression of mCAT attenuated mitochondrial and cellular reactive oxygen species (ROS) and the structural remodeling that was induced by persistent F1759A-Na + current. Despite the heterogeneously prolonged atrial action potential, which was unaffected by the reduction in ROS, the incidences of spontaneous AF, pacing-induced after-depolarizations, and AF were substantially reduced. Expression of mCAT markedly reduced persistent Na + current–induced ryanodine receptor oxidation and dysfunction. In summary, increased persistent Na + current in atrial cardiomyocytes, which is observed in patients with AF, induced atrial enlargement, fibrosis, mitochondrial dysmorphology, early after-depolarizations, and AF, all of which can be attenuated by resolving mitochondrial oxidative stress.
Background: Sepsis is associated with new onset atrial fibrillation (AF), and AF in septic patients is associated with worse outcomes. Serum glucocorticoid kinase 1 (SGK1), a serine/ threonine kinase in the PI-3 kinase pathway, is involved in cardiac inflammation. Prior work has suggested a potential therapeutic role for SGK1 inhibition in cardiac arrhythmias, which we investigated in a model of bacterial sepsis-induced AF. Objective: We sought to determine if 1) CLP, a well established model of polymicrobial sepsis leads to an increased risk of AF, and 2) whether SGK1 inhibition is protective in this model. Methods: Cecal ligation and puncture was performed in male wild type C57/Bl6 (WT) and mice with cardiac specific knockdown of SGK1 (SGK1 DN). Approximately 7 (range 7-9) days after sepsis induction, the mice underwent terminal in vivo electrophysiology studies to determine AF inducibility and basic atrial/ventricular tissue parameters. Additional mice were used to perform optical mapping to determine EP properties and flow cytometry to determine cellular composition.Results: CLP-induced sepsis in WT mice led to high AF inducibility (5 out of 7 mice), as well as AF frequency and burden during EP study. As compared with naïve controls, the AF phenotype was associated with significantly slowed right atrial conduction velocity (0.5460.03 versus 0.6260.08 m/s) along with a similar trend in the left atrium, as measured by optical mapping. Flow cytometry revealed that sepsis increased fibroblasts, macrophages, and neutrophils in the atrial wall when compared to control mice without CLP. When CLP was performed in WT and SGK1 DN littermates, SGK1 DN mice had significantly (p,0.05 by chi-squared) lower AF inducibility (3 out of 8) than the WT mice (7 out of 8). In addition, there was a significant decrease in AF frequency and a trend towards a decrease in total AF burden during the entirety of the EP study. Conclusion: Bacterial sepsis in mice remodels the atrial cell composition and increases AF inducibility. Genetic SGK1 inhibition protected septic mice against AF. These data motivate further investigation into how inflammatory remodeling of atria contributes to sepsis-induced AF, and the potential of SGK1 inhibitors for treatment of this entity.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.